HONG KONG and BEIJING – Not just multinational players but domestic Chinese pharmaceutical companies are poised to benefit from China’s promise under a phase one trade deal with the U.S. to better protect intellectual property (IP), even if question marks remain around how the deal will be enforced. The move is in line with China's ambition to strengthen IP rights protection and upgrade the approach to innovation of its pharmaceutical and biotech industries. Read More

An international collaborative study led by geneticists at the Queensland Institute of Medical Research Berghofer Medical Research Institute (QIMR) in Brisbane, Australia, has used a multivariate approach to develop a polygenic risk score (PRS) for glaucoma. Read More

LONDON – After a second day of deliberation, the World Health Organization (WHO) held off declaring that the novel coronavirus infection raging in Wuhan is an international health emergency, saying the low number of cases outside China means it is not time to escalate the response to this level. Read More

Salt Lake City-based Co-Diagnostics Inc. has finished the principle design work for a polymerase chain reaction (PCR) screening test for the novel coronavirus that has sickened nearly 3,000 with an acute respiratory illness and killed more than 80 people in Wuhan, China. Read More

PERTH, Australia – Australia’s Therapeutic Goods Administration (TGA) is seeking input from industry stakeholders on a proposal to increase its fees to cover projected deficits this year. Read More

BEIJING – With promising phase II data in hand – and newly designated FDA orphan drug status – Suzhou, China-based Tennor Therapeutics Suzhou Co. Ltd. is gearing up to move into pivotal testing with TNP-2092 to treat prosthetic joint infections. Read More

According to Janet Lambert, CEO of the Alliance for Regenerative Medicine (ARM), in her delivery of the international advocacy group’s state of the industry briefing at Biotech Showcase in San Francisco, 2019 proved to be a significant year of growth for the regenerative medicine sector. Read More

The pending Abbvie Inc. merger with Allergan plc, expected to close in the first quarter, brought good tidings to another “A” company on Monday, allowing Astrazeneca plc to regain global rights to its late-stage Crohn’s disease and ulcerative colitis (UC) drug, brazikumab. Read More

Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief, including: Asahi Kasei, Aska Biotheus, Bravovax, Eyepoint, Genentech, Geovax Labs, Hanx, Inovio, Mundipharma, Ningbo Newbay Medical, Ocumension, Onconova, Otsuka, Paion, Phoremost, Pieris, Taiho, Tilt, Veloxis Read More

Biopharmas in Asia-Pacific raising money in public or private financings, including: Biocure Technology, Calidi Biotherapeutics, Hutchison China Meditech, Zai Lab Read More

The latest global regulatory news, changes and updates affecting biopharma, including: Innate Immunotherapeutics, Australia’s Therapeutic Goods Administration Read More

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Astellas, Astrazeneca, Beigene, Cstone, Daiichi Sankyo, Epygenix, Hutchison China Meditech, Isofol Medical, Oric Read More

Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific, including Ascletis, Bridge, Eisai, Ferring, OBI Pharma, Orion, Paion, Tennor Read More